Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

(Bloomberg) -- A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock. Kepler Cheuvreux’s David Evans ...

LONDON - The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 ...

Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE: LLY) owns the other two: Mounjaro and Zepbound. Both Viking and Roche are attempting to horn in on this market, however.

Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down just under 1%. The impact to Novo's stock is largely due to the CagriSema news earlier this week, along with the ...

U.S. shares in Novo Nordisk, a leading maker of anti-obesity drugs, were down roughly 4% Wednesday afternoon. But shares in Eli Lilly, the other major weight-loss player, were little changed.

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...